The Experts below are selected from a list of 1986 Experts worldwide ranked by ideXlab platform
Marcus Maurer - One of the best experts on this subject based on the ideXlab platform.
-
Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
Clinical and Translational Allergy, 2019Co-Authors: Anette Bygum, Andrea Zanichelli, Laurence Bouillet, Irmgard Andresen, Werner Aberer, Teresa Caballero, Hilary Longhurst, Jaco Botha, Anete Grumach, Marcus MaurerAbstract:BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. METHODS: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of Icatibant. We conducted descriptive analyses in younger (age
-
management of patients with hereditary angioedema in germany comparison with other countries in the Icatibant outcome survey
Journal of The European Academy of Dermatology and Venereology, 2019Co-Authors: Marcus Maurer, Irmgard Andresen, Konrad Bork, I Martinezsaguer, Emel Aygorenpursun, Jaco Botha, Markus MagerlAbstract:BACKGROUND The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire-sponsored, international, observational study monitoring the safety and effectiveness of Icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-INH). OBJECTIVE To report IOS data comparing demographic and Icatibant treatment outcomes in patients with HAE-C1-INH from Germany to HAE-C1-INH patients from 11 other IOS countries. METHODS A descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE-C1-INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, Denmark, France, Greece, Israel, Italy, Spain, Sweden and the United Kingdom (n = 592, July 2009-January 2017). Icatibant treatment outcomes were retrieved from patients with complete attack outcome data for time to treatment, time to resolution and attack duration (160 attacks in 42 German patients and 1442 attacks in 251 patients from other IOS countries). RESULTS German patients reported significantly fewer severe/very severe attacks (38.7% vs. 57.5%, respectively; P < 0.001). The proportion of attacks treated with a single Icatibant injection was significantly higher in German patients (97.1% vs. 91.6%, P = 0.0003). The median time to treatment (0.0 h vs. 1.5 h), time to resolution (3.0 h vs. 7.0 h) and attack duration (4.3 h vs. 10.5 h) in German patients vs. other IOS countries were all significantly shorter (all P < 0.0001). No meaningful differences were identified between patients from Germany and other countries with regard to sex, median age at enrolment, median age at symptom onset and median age at diagnosis. CONCLUSION German IOS patients share similar demographic characteristics to patients from other IOS countries yet treat their attacks with Icatibant significantly earlier and have markedly fewer severe or very severe attacks. Factors including regional access to and availability of Icatibant may drive these outcomes and warrant further investigation.
-
Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
Journal of the European Academy of Dermatology and Venereology, 2018Co-Authors: Marcus Maurer, Irmgard Andresen, Konrad Bork, Jaco Botha, I. Martinez‐saguer, Emel Aygören-pürsün, Markus MagerlAbstract:BACKGROUND The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire-sponsored, international, observational study monitoring the safety and effectiveness of Icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-INH). OBJECTIVE To report IOS data comparing demographic and Icatibant treatment outcomes in patients with HAE-C1-INH from Germany to HAE-C1-INH patients from 11 other IOS countries. METHODS A descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE-C1-INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, Denmark, France, Greece, Israel, Italy, Spain, Sweden and the United Kingdom (n = 592, July 2009-January 2017). Icatibant treatment outcomes were retrieved from patients with complete attack outcome data for time to treatment, time to resolution and attack duration (160 attacks in 42 German patients and 1442 attacks in 251 patients from other IOS countries). RESULTS German patients reported significantly fewer severe/very severe attacks (38.7% vs. 57.5%, respectively; P
-
Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P
-
effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight findings from the Icatibant outcome survey a cohort observational study
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P < 0.0001; P = 0.0232 excluding 2 outliers) and treated attacks earlier than patients with normal BMI (P = 0.007). Furthermore, time to resolution and duration of attack were shorter for patients with high BMI (P < 0.001 for overweight and P < 0.05 for obese versus normal). Overall, Icatibant was comparatively effective in treating attacks in patients across all BMI groups. Trial registration NCT01034969.
Irmgard Andresen - One of the best experts on this subject based on the ideXlab platform.
-
Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
Clinical and Translational Allergy, 2019Co-Authors: Anette Bygum, Andrea Zanichelli, Laurence Bouillet, Irmgard Andresen, Werner Aberer, Teresa Caballero, Hilary Longhurst, Jaco Botha, Anete Grumach, Marcus MaurerAbstract:BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. METHODS: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of Icatibant. We conducted descriptive analyses in younger (age
-
management of patients with hereditary angioedema in germany comparison with other countries in the Icatibant outcome survey
Journal of The European Academy of Dermatology and Venereology, 2019Co-Authors: Marcus Maurer, Irmgard Andresen, Konrad Bork, I Martinezsaguer, Emel Aygorenpursun, Jaco Botha, Markus MagerlAbstract:BACKGROUND The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire-sponsored, international, observational study monitoring the safety and effectiveness of Icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-INH). OBJECTIVE To report IOS data comparing demographic and Icatibant treatment outcomes in patients with HAE-C1-INH from Germany to HAE-C1-INH patients from 11 other IOS countries. METHODS A descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE-C1-INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, Denmark, France, Greece, Israel, Italy, Spain, Sweden and the United Kingdom (n = 592, July 2009-January 2017). Icatibant treatment outcomes were retrieved from patients with complete attack outcome data for time to treatment, time to resolution and attack duration (160 attacks in 42 German patients and 1442 attacks in 251 patients from other IOS countries). RESULTS German patients reported significantly fewer severe/very severe attacks (38.7% vs. 57.5%, respectively; P < 0.001). The proportion of attacks treated with a single Icatibant injection was significantly higher in German patients (97.1% vs. 91.6%, P = 0.0003). The median time to treatment (0.0 h vs. 1.5 h), time to resolution (3.0 h vs. 7.0 h) and attack duration (4.3 h vs. 10.5 h) in German patients vs. other IOS countries were all significantly shorter (all P < 0.0001). No meaningful differences were identified between patients from Germany and other countries with regard to sex, median age at enrolment, median age at symptom onset and median age at diagnosis. CONCLUSION German IOS patients share similar demographic characteristics to patients from other IOS countries yet treat their attacks with Icatibant significantly earlier and have markedly fewer severe or very severe attacks. Factors including regional access to and availability of Icatibant may drive these outcomes and warrant further investigation.
-
Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
Journal of the European Academy of Dermatology and Venereology, 2018Co-Authors: Marcus Maurer, Irmgard Andresen, Konrad Bork, Jaco Botha, I. Martinez‐saguer, Emel Aygören-pürsün, Markus MagerlAbstract:BACKGROUND The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire-sponsored, international, observational study monitoring the safety and effectiveness of Icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-INH). OBJECTIVE To report IOS data comparing demographic and Icatibant treatment outcomes in patients with HAE-C1-INH from Germany to HAE-C1-INH patients from 11 other IOS countries. METHODS A descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE-C1-INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, Denmark, France, Greece, Israel, Italy, Spain, Sweden and the United Kingdom (n = 592, July 2009-January 2017). Icatibant treatment outcomes were retrieved from patients with complete attack outcome data for time to treatment, time to resolution and attack duration (160 attacks in 42 German patients and 1442 attacks in 251 patients from other IOS countries). RESULTS German patients reported significantly fewer severe/very severe attacks (38.7% vs. 57.5%, respectively; P
-
Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P
-
effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight findings from the Icatibant outcome survey a cohort observational study
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P < 0.0001; P = 0.0232 excluding 2 outliers) and treated attacks earlier than patients with normal BMI (P = 0.007). Furthermore, time to resolution and duration of attack were shorter for patients with high BMI (P < 0.001 for overweight and P < 0.05 for obese versus normal). Overall, Icatibant was comparatively effective in treating attacks in patients across all BMI groups. Trial registration NCT01034969.
Andrea Zanichelli - One of the best experts on this subject based on the ideXlab platform.
-
Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
Clinical and Translational Allergy, 2019Co-Authors: Anette Bygum, Andrea Zanichelli, Laurence Bouillet, Irmgard Andresen, Werner Aberer, Teresa Caballero, Hilary Longhurst, Jaco Botha, Anete Grumach, Marcus MaurerAbstract:BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. METHODS: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of Icatibant. We conducted descriptive analyses in younger (age
-
effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight findings from the Icatibant outcome survey a cohort observational study
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P < 0.0001; P = 0.0232 excluding 2 outliers) and treated attacks earlier than patients with normal BMI (P = 0.007). Furthermore, time to resolution and duration of attack were shorter for patients with high BMI (P < 0.001 for overweight and P < 0.05 for obese versus normal). Overall, Icatibant was comparatively effective in treating attacks in patients across all BMI groups. Trial registration NCT01034969.
-
Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P
-
Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
BMC, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Irmgard Andresen, Werner Aberer, Marcus Maurer, The Ios Study GroupAbstract:Abstract Background Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Methods Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Results Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P
-
MOESM1 of Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Additional file 1. Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
Werner Aberer - One of the best experts on this subject based on the ideXlab platform.
-
Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
Clinical and Translational Allergy, 2019Co-Authors: Anette Bygum, Andrea Zanichelli, Laurence Bouillet, Irmgard Andresen, Werner Aberer, Teresa Caballero, Hilary Longhurst, Jaco Botha, Anete Grumach, Marcus MaurerAbstract:BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. METHODS: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of Icatibant. We conducted descriptive analyses in younger (age
-
effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight findings from the Icatibant outcome survey a cohort observational study
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P < 0.0001; P = 0.0232 excluding 2 outliers) and treated attacks earlier than patients with normal BMI (P = 0.007). Furthermore, time to resolution and duration of attack were shorter for patients with high BMI (P < 0.001 for overweight and P < 0.05 for obese versus normal). Overall, Icatibant was comparatively effective in treating attacks in patients across all BMI groups. Trial registration NCT01034969.
-
Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P
-
Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
BMC, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Irmgard Andresen, Werner Aberer, Marcus Maurer, The Ios Study GroupAbstract:Abstract Background Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Methods Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Results Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P
-
MOESM1 of Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Additional file 1. Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
Laurence Bouillet - One of the best experts on this subject based on the ideXlab platform.
-
Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
Clinical and Translational Allergy, 2019Co-Authors: Anette Bygum, Andrea Zanichelli, Laurence Bouillet, Irmgard Andresen, Werner Aberer, Teresa Caballero, Hilary Longhurst, Jaco Botha, Anete Grumach, Marcus MaurerAbstract:BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. METHODS: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of Icatibant. We conducted descriptive analyses in younger (age
-
Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P
-
effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight findings from the Icatibant outcome survey a cohort observational study
Clinical and Translational Allergy, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P < 0.0001; P = 0.0232 excluding 2 outliers) and treated attacks earlier than patients with normal BMI (P = 0.007). Furthermore, time to resolution and duration of attack were shorter for patients with high BMI (P < 0.001 for overweight and P < 0.05 for obese versus normal). Overall, Icatibant was comparatively effective in treating attacks in patients across all BMI groups. Trial registration NCT01034969.
-
Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
BMC, 2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Irmgard Andresen, Werner Aberer, Marcus Maurer, The Ios Study GroupAbstract:Abstract Background Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of Icatibant is not documented in the literature. We examined disease characteristics and Icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongoing, international, observational study monitoring the real-world safety and effectiveness of Icatibant. Methods Attack and treatment characteristics as well as outcomes following treatment with Icatibant were compared among patients with underweight, normal, overweight, and obese BMI. Results Data from 2697 Icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single Icatibant injection without the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used pdC1-INH as rescue treatment more often (P
-
MOESM1 of Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
2018Co-Authors: Teresa Caballero, Hilary Longhurst, Andrea Zanichelli, Laurence Bouillet, Werner Aberer, Marcus Maurer, Irmgard AndresenAbstract:Additional file 1. Effectiveness of Icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
